Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Progress Report”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 91 records · Page 5Linked to original sources
PubMedDate not supplied

A computerized information system for evaluation of NLEP through monthly progress reports.

A computerized system for monitoring district-wise operational performance and epidemiological progress using existing regular and special monthly reports of the National Leprosy Eradication Programme (NLEP) is presented. The same system, with some minor modifications could be used for programme assessment at the Leprosy Control Unit level also. The advantage of the system is the speed with which it can generate output in the form of comparative tables and graphs for different regions for use by programme managers for making overall assessments in time and for sending feedback reports to workers at various levels, for self-assessment and for taking timely corrective action. The system presented provides immediate and easy access to the stored and/or processed information (indicators etc.,) at any time. The system has been pilot-tested using monthly reports from eighteen districts of Tamil Nadu.

Databases, Factual↗
PubMed1988

Progress report.

Explore the source record for details and available documents.

Africa↗
PubMed2003

Usefulness of specific IgE antibody tests: a progress report.

LEARNING OBJECTIVES: To enable the readers to recognize some of the history, problems, progress, interpretation, and present status of assays for specific IgE (s-IgE) antibodies. DATA SOURCES: Peer-reviewed literature in the field. STUDY SELECTION: Key articles were selected by the author. RESULTS: Clinical and analytical studies have differed widely in their conclusions as to the performance of tests for s-IgE. Study conclusions depend on the testing method used, the allergen(s) studied, patient selection, and, most importantly, the standards used for comparison. Today, only a handful of the once commercially developed assays still exist, and some of these still do not compare well to an analytical ideal standard. However, with the extent of regulation and economic pressures, most of the surviving s-IgE tests are considerably improved over what had existed before them. CONCLUSIONS: Allergic diseases with multiple symptom patterns seem to be increasing in modern societies. Objective methods are needed to differentiate allergic origins from other mechanisms that cause similar symptoms. Accurate, quantitative, and objective methods for s-IgE measurement are now available and can be used effectively in clarifying allergic diagnoses when interpreted in conjunction with the clinical history.

Antibody Specificity↗
PubMed1995

[Progress report on a World Bank loan to China for a tuberculosis control project].

The progress of the World Bank loaned TB control project implemented from the second quarter of 1991 to the fourth quarter of 1993 was described in this paper. In the past three years, 737 counties of the 12 provinces with the population of 360 million has been covered by the project. Among 95176 new smear positive cases discovered, 93909 patients received free treatment of TB. The treatment coverage is 98.7%, of which 95% were treated under full course supervision. The smear conversion rate at two, three months of new smear positive TB patients are 83.4% and 90.6% respectively. The cohort analysis showed that the cure rate is 89.8%, which has reached the advanced level of the modern national tuberculosis control programme in the world.

Adolescent↗
PubMedDate not supplied

The alpha 2 (r) interferon in the treatment of hairy cell leukemia: progressive report of 25 cases.

Twenty-five patients with Hairy Cell Leukemia (HCL), eleven in post-splenectomy progressive disease, have been treated as out-patients with alpha 2 (r) Interferon (IFN) for twelve months. Eighteen patients completed the treatment: four achieved Complete Response (CR), twelve Partial Response (PR) and two Minor Response (MR). The response to IFN has been CR or PR in 89% of cases and MR in 11%. Even if the IFN effective dose and the length of treatment remain to be determined, IFN at relatively low dose seems to become the first treatment of choice in HCL patients. The remaining seven patients, still under treatment, already achieved PR at least.

Adult↗
PubMed1996

A prospective study of congenital melanocytic naevi: progress report and evaluation after 6 years.

A prospective study of children with large congenital melanocytic naevi (CMNs) is in progress. Its aims are to observe the natural history and inheritance of CMNs, to record associated pathologies, and eventually to evaluate the effects of treatment. Information is obtained by patient-completed questionnaires and clinical assessment. One hundred and thirty-three children have been followed for a total of 452 patient years. The female/male ratio is 3:2. The characteristics, size and distribution at birth of the CMNs in this group of patients, and their development and associated abnormalities, are documented. After 5 years, affected children were compared with a matched cohort of normal children. Although the prevalence of neurological and developmental defects was higher in affected children, no malignant melanomas have been reported to date. The families of affected children had higher numbers of naevi and café-au-lait spots than those of normal children, suggesting a possible hereditary component. The mothers of affected children also reported an increased incidence of influenza-like illness and of severe nausea and vomiting in pregnancy. This study will continue for a further 4 years, in the first instance, after which we will seek relationships between characteristics of the naevi and outcome.

Adolescent↗
PubMed1986

Progress report--clinical pathology consultations. CAP Reimbursement Committee.

The CAP Washington office, under the aegis of the Council on Government and Professional Affairs, provides information and guidance to College members and state pathology societies on relationships of pathologists with governmental bodies, and on reimbursement issues. This article reports the findings of a survey conducted in autumn of 1985 to assess progress in implementation of reimbursement for clinical pathology consultations by the Medicare carriers.

Data Collection↗
PubMed1996

A progress report of cancer centers and tribal communities. Building a partnership based on trust.

BACKGROUND: Over the past 20 years, considerable progress has been made in the early detection and treatment of cancer. Despite these advances, cancer incidence and mortality rates among Native Americans have not kept pace. Cancer centers are in a unique position to offer technical assistance, resources, and a long term commitment that can help address these concerns within tribal communities. METHODS: The University of Wisconsin Comprehensive Cancer Center developed a proactive plan to build collaborative partnerships with Wisconsin Native Americans. This began with an outreach plan that prioritized intervention strategies. A Native American health professional was hired to serve as liaison and advocate. Resources were committed, and staff was assigned to work with the community to develop intervention strategies that would be culturally competent and able to address the concerns of community members. RESULTS: Various collaborative activities resulted from these efforts. These included participation in Native American cancer work groups, conferences, and seminars. Most importantly, these efforts resulted in a partnership with the Native American community that is based on honor and mutual respect. CONCLUSIONS: Careful planning, prioritization, allocation of resources, and a commitment to Native Americans can result in partnerships with the community and interventions that address their cancer control needs. Building and sustaining these partnerships takes time and thoughtful exploration of issues and concerns to develop mutual trust and respect. Both cancer centers and tribal communities can benefit by recognizing that shared power, as a reciprocal value, can benefit the whole.

Academic Medical Centers↗
PubMedDate not supplied

National randomized study of chemotherapeutic agents in advanced prostatic carcinoma: a progress report.

In the 36 months since its inception, the National Prostatic Cancer Project treatment subgroup has randomly assigned over 360 patients with progressive advanced prostatic cancer who were no longer responsive to endocrine manipulation to either one of four different clinical studies. The initial study demonstrated a clear superiority for 5-fluorouracil (5-FU) and cyclophosphamide over continued conventional therapy. Beneficial responses were documented and are associated with increased survival rates and relief from pain and other symptoms. A proportionately larger number of patients obtained clinical benefit (stable and partial regression) on cyclophosphamide than on standard or 5-FU therapy. The criteria for evaluation of patients are supported by the survival data, ie, responders have survived for a longer period of time than those patients who continued in progression. Preliminary data from the subsequent protocols have documented a 30% response (stable and partial regression) in patients receiving oral estramustine phosphate and definite responses in patients treated with DTIC; Too few patients have been treated with Leo 1031 to offer total response rates at this time, although the early results are promising. These clinical studies have firmly established a place for chemotherapy in the management of prostatic cancer. New trials will introduce single- and multiple-drug chemotherapy at earlier phases of the clinical course of prostatic cancer patients.

Carcinoma↗
PubMed2004

The PROMiSe trial: baseline data review and progress report.

The PROMiSe trial is a multinational, multicentre, double-blind, placebo-controlled trial evaluating the effects of glatiramer acetate treatment over 3 years in patients with primary progressive multiple sclerosis (PPMS). A total of 943 patients were enrolled, and all those remaining on-study had completed at least 24 months as of October 2002. Baseline clinical and MRI characteristics and select correlations are reported here. A total of 3.9% of patients exhibited confirmed relapse over 1904 patient-years of exposure, indicating success of efforts to exclude relapsing MS types. Of the 26.3% of patients who have prematurely withdrawn from the study, only 36% discontinued after meeting the study primary endpoint of disease progression. The progression rate in patients in the low Expanded Disability Status Scale (EDSS) stratum (3.0-5.0) observed thus far is markedly lower than the 50% annual progression rate estimate used for determining size and statistical power of the trial; progression was observed in 16.1% of patients with 12 months of study exposure. These early findings raise some concern about the ability of the trial to demonstrate a significant treatment effect, and suggest that the short-term natural history of PPMS may not be as aggressive as previously assumed.

Adjuvants, Immunologic↗
PubMed1980

Progress report on controlled trial of fecal occult blood testing for the detection of colorectal neoplasia.

Our controlled trial of screening for colorectal cancer has now been in progress for almost five years. Screening is accomplished by rigid sigmoidoscopy in control and study groups and, in addition, by fecal occult blood testing in the study group. Patients screened are men and women age 40 and older, mostly at average risk. Fecal occult blood testing is with Hemoccult slides with patients on a meat-free, high-bulk diet without hydration, and with a four-day storage interval between slide preparation and testing. Patients with positive slides undergo diagnostic investigation that includes both colonoscopy and double-contrast barium enema and, in some, an upper gastrointestinal series. Preliminary results to date include: patient baseline statistics and subgroup comparability, rate of positive slides of 1-4%, predictive value for neoplasia of 44-50%, false-positives of 0.5-2.1%, favorable Dukes' staging of cancers in the study group, and high patient compliance. Considerably more follow-up is need in our study and control population, and issues such as mortality and cost need to be addressed. Additional time will be necessary to provide firm conclusions.

Adenoma↗
PubMed1988

The asymmetric dimeric polymerase hypothesis: a progress report.

In 1983, my laboratory first proposed that the DNA polymerase III holoenzyme is an asymmetric dimer with distinguishable leading and lagging strand polymerases. Here, I review progress by my laboratory and others in testing this hypothesis. To date, the hypothesis is supported by our demonstration of (i) an asymmetry in function of two populations of holoenzyme in solution in their ability to use the ATP analog, ATP gamma S, to support initiation complex formation, (ii) the stabilization of a dimeric polymerase structure by the tau subunit, (iii) allosteric communication between polymerase halves and (iv) the coexistence of gamma and the tau, subunits which share common sequences, within the same holoenzyme assemblies. This latter observation may provide a structural basis for holoenzyme asymmetry. I discuss the implications of the asymmetric dimer hypothesis to the solution of problems encountered by polymerases at the replication fork and delineate further tests required before the hypothesis can be firmly established.

Adenosine Triphosphate↗
PubMed1991

The World Health Organisation goals for oral health: a progress report.

Global oral health goals for the year 2000 were adopted in 1981 by the World Health Organisation. A literature review and collation of available data relating to progress towards these goals have been carried out. Their appropriateness and value as measures of oral health and disease trends are discussed. The general conclusions of the study were that the concept of global goals was valuable but that the lack of standardised data collection and publication made it difficult to evaluate progress towards attainment of the goals.

Adolescent↗